FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097620013> ?p ?o ?g. }

• W2097620013 endingPage "168" @default.
• W2097620013 startingPage "161" @default.
• W2097620013 abstract "Previously we detected more than 3 times higher anti-cholesterol antibody (ACHA) levels in HIV positive patients compared to healthy individuals, however, this level significantly decreased during highly active anti-retroviral therapy (HAART). In our present study we examined whether these findings could also be detected in patients with chronic hepatitis C (CHC). We calculated the correlation between the ACHA levels and the C5b-9 complement activation product. 39 patients with CHC were treated with IFN-alpha-2b (Schering-Plough) 5 MU daily for 6 weeks, followed by 5 MU TIW. Serum levels of ACHA and complement activation products were measured with ELISA. Serum HCV RNA was measured by a highly sensitive branched DNA technique before and 3, 6 and 12 months after the beginning of IFN-alpha-2b therapy. 52 healthy persons served as controls. At the onset of treatment ACHA level was significantly (p = 0.0062) higher in patients (40 (24-69) AU/ml) (median (interquartile range)) than in control sera (26 (20-35) AU/ml). In the 26 responder patients ACHA levels decreased to the normal level during the therapy, but no change was observed in the 13 non-responders. In patients with a sustained response ACHA levels remained low till the end of the 12 months IFN treatment. ACHA levels were significantly (p = 0.0422) higher in the patients with low (< 4.0 mmol/l) than in those with normal (> or = 4.0 mmol/l) cholesterol concentrations. The ACHA level before the therapy strongly correlated (r = 0.5499, p = 0.0014) with C5b-9 serum levels. ACHA levels are elevated in CHC, but this elevation is not as high as in HIV. Decrease of viral load by IFN-alpha-2b treatment in the responders results in normalization of ACHA concentration. High ACHA levels in patients with low serum cholesterol concentration suggest that high ACHA levels may contribute to the decrease in cholesterol levels. The correlation between the ACHA and C5b-9 levels indicate, that the ACHA may play a role in the complement activation in CHC." @default.
• W2097620013 created "2016-06-24" @default.
• W2097620013 creator A5001183274 @default.
• W2097620013 creator A5001559505 @default.
• W2097620013 creator A5016224431 @default.
• W2097620013 creator A5019391237 @default.
• W2097620013 creator A5031820121 @default.
• W2097620013 creator A5034988275 @default.
• W2097620013 creator A5041500795 @default.
• W2097620013 creator A5042234744 @default.
• W2097620013 creator A5047323279 @default.
• W2097620013 creator A5064774239 @default.
• W2097620013 creator A5065300194 @default.
• W2097620013 creator A5065915339 @default.
• W2097620013 creator A5070129943 @default.
• W2097620013 creator A5076163230 @default.
• W2097620013 creator A5077740144 @default.
• W2097620013 creator A5081492922 @default.
• W2097620013 creator A5079862821 @default.
• W2097620013 date "2003-01-01" @default.
• W2097620013 modified "2023-10-09" @default.
• W2097620013 title "Serum Anti-cholesterol Antibodies in Chronic Hepatitis-C Patients During IFN-?-2b Treatment" @default.
• W2097620013 cites W1531286087 @default.
• W2097620013 cites W1538132292 @default.
• W2097620013 cites W1968471192 @default.
• W2097620013 cites W1984084256 @default.
• W2097620013 cites W1990544547 @default.
• W2097620013 cites W1992089894 @default.
• W2097620013 cites W2001070009 @default.
• W2097620013 cites W2005304397 @default.
• W2097620013 cites W2024132564 @default.
• W2097620013 cites W2027420898 @default.
• W2097620013 cites W2030958539 @default.
• W2097620013 cites W2044251142 @default.
• W2097620013 cites W2054862747 @default.
• W2097620013 cites W2076955144 @default.
• W2097620013 cites W2079710283 @default.
• W2097620013 cites W2087159485 @default.
• W2097620013 cites W2088643134 @default.
• W2097620013 cites W2092377023 @default.
• W2097620013 cites W2115956200 @default.
• W2097620013 cites W2117134676 @default.
• W2097620013 cites W2127869931 @default.
• W2097620013 cites W2153082215 @default.
• W2097620013 cites W2159913400 @default.
• W2097620013 cites W2265709802 @default.
• W2097620013 cites W2394544815 @default.
• W2097620013 cites W2395546240 @default.
• W2097620013 doi "https://doi.org/10.1078/0171-2985-00229" @default.
• W2097620013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12777057" @default.
• W2097620013 hasPublicationYear "2003" @default.
• W2097620013 type Work @default.
• W2097620013 sameAs 2097620013 @default.
• W2097620013 citedByCount "12" @default.
• W2097620013 countsByYear W20976200132016 @default.
• W2097620013 countsByYear W20976200132019 @default.
• W2097620013 countsByYear W20976200132020 @default.
• W2097620013 crossrefType "journal-article" @default.
• W2097620013 hasAuthorship W2097620013A5001183274 @default.
• W2097620013 hasAuthorship W2097620013A5001559505 @default.
• W2097620013 hasAuthorship W2097620013A5016224431 @default.
• W2097620013 hasAuthorship W2097620013A5019391237 @default.
• W2097620013 hasAuthorship W2097620013A5031820121 @default.
• W2097620013 hasAuthorship W2097620013A5034988275 @default.
• W2097620013 hasAuthorship W2097620013A5041500795 @default.
• W2097620013 hasAuthorship W2097620013A5042234744 @default.
• W2097620013 hasAuthorship W2097620013A5047323279 @default.
• W2097620013 hasAuthorship W2097620013A5064774239 @default.
• W2097620013 hasAuthorship W2097620013A5065300194 @default.
• W2097620013 hasAuthorship W2097620013A5065915339 @default.
• W2097620013 hasAuthorship W2097620013A5070129943 @default.
• W2097620013 hasAuthorship W2097620013A5076163230 @default.
• W2097620013 hasAuthorship W2097620013A5077740144 @default.
• W2097620013 hasAuthorship W2097620013A5079862821 @default.
• W2097620013 hasAuthorship W2097620013A5081492922 @default.
• W2097620013 hasConcept C119060515 @default.
• W2097620013 hasConcept C126322002 @default.
• W2097620013 hasConcept C134018914 @default.
• W2097620013 hasConcept C159654299 @default.
• W2097620013 hasConcept C203014093 @default.
• W2097620013 hasConcept C2522874641 @default.
• W2097620013 hasConcept C2776455275 @default.
• W2097620013 hasConcept C2778163477 @default.
• W2097620013 hasConcept C3020491458 @default.
• W2097620013 hasConcept C71924100 @default.
• W2097620013 hasConcept C90924648 @default.
• W2097620013 hasConceptScore W2097620013C119060515 @default.
• W2097620013 hasConceptScore W2097620013C126322002 @default.
• W2097620013 hasConceptScore W2097620013C134018914 @default.
• W2097620013 hasConceptScore W2097620013C159654299 @default.
• W2097620013 hasConceptScore W2097620013C203014093 @default.
• W2097620013 hasConceptScore W2097620013C2522874641 @default.
• W2097620013 hasConceptScore W2097620013C2776455275 @default.
• W2097620013 hasConceptScore W2097620013C2778163477 @default.
• W2097620013 hasConceptScore W2097620013C3020491458 @default.
• W2097620013 hasConceptScore W2097620013C71924100 @default.
• W2097620013 hasConceptScore W2097620013C90924648 @default.
• W2097620013 hasIssue "3" @default.

• next